Immunologically Active Compositions for Mucosal Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines and immune modulators face challenges in inducing effective protective immunity, particularly against rapidly mutating pathogens like influenza and HIV, and in overcoming immune escape mechanisms, with traditional vaccines often requiring high antigen doses and struggling with mucosal administration and stability issues.
Innovation Solution
Development of immunologically active compositions comprising antigenic epitopes, pathogen-associated molecular patterns (PAMPs), and carriers that exclude escape epitopes, along with methods for identifying immune-active molecules, such as those using heparin adsorption and immunoaffinity selection, to induce protective immunity or tolerance, and the use of microparticles as delivery vehicles that can target specific immune cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If traditional vaccines use whole pathogens or high antigen doses, then immune coverage is broad, but immune escape mechanisms are activated and tolerance is induced
Solution Approach 1:
The patent extracts and isolates specific protective epitopes from whole pathogens, using only the essential immunogenic components that induce protective immunity without triggering immune escape or tolerance mechanisms
Solution Approach 2:
The patent applies local quality by designing vaccines with specific epitope compositions tailored to induce Th1 responses in particular tissue compartments (mucosal vs. systemic), using different epitope combinations for different anatomical locations
2Ease of operation
If vaccines are administered parenterally, then delivery is simple, but mucosal immunity is less pronounced
Solution Approach 1:
The patent uses mucosal adjuvants and delivery systems (such as cholera toxin derivatives, heat-labile toxin, and engineered bacterial vectors) as intermediaries to facilitate antigen delivery to mucosal-associated lymphoid tissues and induce robust mucosal immune responses
Solution Approach 2:
The patent changes the physical and chemical parameters of vaccine delivery by using mucosal routes (oral, nasal, inhalation) instead of parenteral injection, and by formulating antigens with mucosal-adjuvant complexes that enhance uptake by mucosal antigen-presenting cells
3Force
If innate immune pathways (TLR signaling) are stimulated, then inflammatory response is activated, but additional pathways (NOD, Mindin) are required for effective control
Solution Approach 1:
The patent merges multiple immune pathway activation by combining TLR agonists with NOD ligands and Mindin activators in single vaccine formulations, creating synergistic effects that simultaneously engage innate immune pathways for enhanced protective immunity
Solution Approach 2:
The patent uses composite adjuvant systems that combine multiple molecular patterns (TLR ligands, NOD agonists, Mindin activators) in defined ratios to simultaneously stimulate multiple innate immune pathways and achieve balanced Th1/Th2 responses
4Reliability
If dendritic cells are activated to link innate and adaptive immunity, then immune response is enhanced, but antigen presentation requirements become more specific
Solution Approach 1:
The patent segments the antigen into distinct epitope components that are separately optimized for MHC class I and MHC class II presentation, ensuring efficient activation of both CD8+ and CD4+ T cell responses through dendritic cell processing pathways
Data Source
AI summary
This invention provides a microparticle carrier system comprising of one or more proteins, peptides, nucleic acids, carbohydrates, lipids or other bioactive substances with or without targeting molecules attached. In addition, the invention also provides immune modulatory compositions and methods of eliciting protective immune responses both in uninfected and infected hosts as well as the induction of immune tolerance.